Endonovo Therapeutics, Inc.

ENDV

Financials

10-QQ3 ended 09/30/2312/29/23 10-Q/AQ3 ended 09/30/2312/29/23 10-QQ2 ended 06/30/2308/21/23 10-QQ1 ended 03/31/2305/22/23 10-KFY 202204/17/23

Disclosures

8-KCurrent report01/03/24 8-KCurrent report12/04/23 8-KCurrent report10/12/23 8-KCurrent report03/29/23 8-KCurrent report09/27/22

Prospectuses and Registrations

424B3Prospectus07/16/20 S-1/ARegistration statement (amended)07/10/20 S-1Registration statement (IPO)06/23/20 POS AMPost-effective amendment06/02/20 S-1/ARegistration statement (amended)01/08/19

Proxies

DEF 14ADefinitive proxy11/14/19 DEF 14CDefinitive information statement11/14/19 PRE 14CPRE 14C10/31/19 DEF 14CDefinitive information statement08/28/18 PRE 14CPRE 14C08/14/18

Ownership

Form 4Insider transaction07/07/20 Form 4Insider transaction02/26/20 4/AInsider transaction (amended)01/24/20 4/AInsider transaction (amended)01/24/20 Form 4Insider transaction01/23/20

Other

SEC STAFF ACTIONSEC staff action09/19/24 15-12GCertification of termination of registration02/02/24 NT 10-QLate filing notification (10-Q)11/15/23 1-A/A1-A/A08/25/23 NT 10-QLate filing notification (10-Q)08/15/23